- Genomic Health update2 days ago
@UrologyPractice publishes study showing #Oncotype DX increases use of #activesurveillance by #prostatecancer patients by 56 percent. The multi-center decision impact study of Genomic Health's prostate cancer test underscores the opportunity for more precise management of low-risk disease. Read more: http://glassdoor.com/slink.htm?key=vIKrX
- Genomic Health update30 days ago
We're BBQ-ing today to celebrate #IndependenceDay! What are your #July4 traditions?
Genomic Health, a global health company founded in August of 2000 and located in Redwood City, California, is committed to improving the quality of cancer treatment decisions through the research, development and commercialization of genomic-basedclinical laboratory services. To that end, the company conducts sophisticated genomic research to develop clinically-validated molecular diagnostics which provide individualized information on response to certain types of therapy, as well as the likelihood of disease recurrence. These diagnostic technologies generate information that healthcare providers and patients can use in making treatment decisions.
At Genomic Health, we developed and follow a highly specialized process that not only adheres rigorously to CAP (College of American Pathologists) standards and CLIA (Clinical Laboratory Improvement Amendments) regulations, but also incorporates numerous real-time quality checks and periodic proficiency testing designed to produce a high level of accuracy in information that we deliver to physicians and patients.
The company's lead product, the Oncotype DX breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer and has been shown to predict the likelihood of recurrence in ductal carcinoma in situ (DCIS). In addition to this widely adopted test, Genomic Health provides theOncotype DX colon cancer test, the first multi-gene expression test developed for the assessment of risk of recurrence in patients with stage II and stage III disease and the Oncotype DX prostate cancer test, which predicts disease aggressiveness in men with low risk disease. Genomic Health has a robust pipeline focused on developing tests to further optimize the treatment of breast, colon and prostate cancers, as well as the treatment of renal cancer.
Life at Genomic Health
At Genomic Health, you have the opportunity to make a difference in the lives of patients with cancer while developing your career potential. You will be encouraged to connect, communicate and innovate in a supportive environment characterized by transparency, clarity, and collaboration. From frequent and real-time feedback to a reward system that recognizes achievements and results, you will find that every contribution is valued and excellence is our goal. We celebrate accomplishments, promote career growth, and encourage a healthy work/life balance.
Genomic Health Photos
- Work/Life Balance
- Culture & Values
- Career Opportunities
- Comp & Benefits
- Senior Management
I have been working at Genomic HealthRecommendsPositive OutlookApproves of CEORecommendsPositive OutlookApproves of CEO
Very nice co-workers and environments
project plans are not clear
Getting an Interview
Getting an Interview
- No OfferNeutral ExperienceAverage Interview
I applied online. The process took 2+ months – interviewed at Genomic Health in March 2015.
The interview took around 45 minutes with very in-depth questions about my project at school. Not many questions about my past experience. I think that is the way the interviewer figured out whether I did contribute anything for the project and whether I really led the team as I mentioned. They had not come back to me after that although I pinged them sometimes. Thus I think that is the way they say "No".
- How did you do when there was a conflict in your team Answer Question
Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient's journey. The company’s Oncotype DX® portfolio of breast, colon and prostate cancer tests apply ...